Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P06858

UPID:
LIPL_HUMAN

ALTERNATIVE NAMES:
Phospholipase A1

ALTERNATIVE UPACC:
P06858; B2R5T9; Q16282; Q16283; Q96FC4

BACKGROUND:
The enzyme Lipoprotein lipase, with an alternative name of Phospholipase A1, is central to the metabolism of triglycerides. It breaks down triglycerides from circulating lipoproteins, aiding in lipid clearance from the blood and lipid storage. Its activity is crucial for maintaining lipid homeostasis, with a significant impact on overall cardiovascular health. The enzyme's interaction with GPIHBP1 and heparan sulfate proteoglycans on endothelial surfaces underscores its importance in lipid processing.

THERAPEUTIC SIGNIFICANCE:
Disruptions in Lipoprotein lipase function are implicated in severe metabolic conditions such as Hyperlipoproteinemia 1 and Familial Combined Hyperlipidemia 3, underscoring the enzyme's therapeutic potential. Targeting Lipoprotein lipase activity could provide a strategic approach to managing these disorders, highlighting the enzyme's significance in developing treatments for lipid-related diseases and their cardiovascular complications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.